Deucravacitinib in patients with plaque psoriasis who did not have adequate response to apremilast is effective and ...

Two-year real-world data highlight strong drug survival and effectiveness of bimekizumab in plaque psoriasis. Learn more ...

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the first patient has been dosed in a global Phase 2 clinical trial (NCT06380907) ...

Reader's DigestHome Remedies for Eczema and Psoriasis ReliefSave money on expensive skin care treatments and try these homemade remedies first. Plaque psoriasis is a skin disease that causes raised ...

On January 21, Chardan initiated coverage of Alumis with a Buy rating and a $37 price target driven by the significant ...

The retrospective analysis, published in the Journal of Clinical Medicine, supports the use of tildrakizumab, an interleukin-23 (IL-23) inhibitor that was FDA approved in 2018 for moderate-to-severe ...

84% of adolescents with moderate-to-severe plaque psoriasis treated with investigational icotrokinra achieved clear or almost clear skin (IGA 0/1) at Week 16 ICONIC-LEAD is the first ever Phase 3 ...

Takeda’s zasocitinib has shown strong rates of skin clearance, as well as other benefits, in new study results regarding adults with moderate-to-severe plaque psoriasis (PsO).

Since revealing her plaque psoriasis diagnosis in 2015, La La Anthony has become a powerful voice for those living with the chronic skin condition. Plaque psoriasis—often mistaken for dry skin or ...

ICONIC-LEAD is the first ever Phase 3 registrational study in moderate-to-severe plaque psoriasis to assess safety and efficacy of a systemic therapy in adolescents and adults simultaneously 84% of ...